ADARx posts Q3 2026 results after $602.5M IPO and AbbVie placement; onvuzosiran gets FDA Fast Track for HAE
ADARx Pharmaceuticals reported Q3 2026 results on November 12, 2026, with a net loss of $28.1 million and $901.0 million in cash, which it expects to fund operations into 2030. The company closed its Nasdaq IPO and a concurrent AbbVie private placement for about $602.5 million in gross proceeds. In August 2026 the FDA granted Fast Track designation to onvuzosiran for HAE prophylaxis, and the Phase 3 STOP-HAE trial is expected to read out by the end of 2027. Three Phase 2 trials of agazisiran in complement-mediated diseases are ongoing.
Company's press release (SEC filing): ADARx Pharmaceuticals, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M
Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597
Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants
Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities
Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds
